Manulife (Manufacturers Life Insurance)
NRIX icon

Manulife (Manufacturers Life Insurance)’s Nurix Therapeutics NRIX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.78M Buy
179,177
+6,813
+4% +$113K ﹤0.01% 1366
2025
Q4 		$3.28M Buy
172,364
+147,012
+580% +$2.11M ﹤0.01% 1345
2025
Q3 		$234K Sell
25,352
-11,862
-32% -$123K ﹤0.01% 2500
2025
Q2 		$424K Buy
37,214
+5,647
+18% +$61K ﹤0.01% 2244
2025
Q1 		$375K Buy
31,567
+542
+2% +$9.06K ﹤0.01% 2267
2024
Q4 		$585K Buy
31,025
+642
+2% +$14.7K ﹤0.01% 2166
2024
Q3 		$683K Buy
30,383
+7,441
+32% +$169K ﹤0.01% 2116
2024
Q2 		$479K Buy
22,942
+4,583
+25% +$71.4K ﹤0.01% 2239
2024
Q1 		$270K Sell
18,359
-885
-5% -$9.52K ﹤0.01% 2445
2023
Q4 		$199K Hold
19,244
– – ﹤0.01% 2631
2023
Q3 		$151K Hold
19,244
– – ﹤0.01% 2685
2023
Q2 		$192K Buy
19,244
+1,070
+6% +$10.9K ﹤0.01% 2625
2023
Q1 		$161K Sell
18,174
-43,164
-70% -$450K ﹤0.01% 2635
2022
Q4 		$672K Buy
61,338
+481
+0.8% +$5.8K ﹤0.01% 1815
2022
Q3 		$787K Sell
60,857
-493
-0.8% -$7.8K ﹤0.01% 1714
2022
Q2 		$770K Sell
61,350
-5,350
-8% -$60.6K ﹤0.01% 1768
2022
Q1 		$943K Buy
66,700
+50,318
+307% +$893K ﹤0.01% 1787
2021
Q4 		$487 Sell
16,382
-63
-0.4% -$1.91K ﹤0.01% 2282
2021
Q3 		$493K Sell
16,445
-1,375
-8% -$42.4K ﹤0.01% 2297
2021
Q2 		$473K Buy
17,820
+4,510
+34% +$132K ﹤0.01% 2476
2021
Q1 		$414K Buy
13,310
+6,290
+90% +$238K ﹤0.01% 2413
2020
Q4 		$231K Buy
7,020
+1,085
+18% +$36K ﹤0.01% 2688
2020
Q3 		$207K Buy
+5,935
New +$150K ﹤0.01% 2541

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s NRIX Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Nurix Therapeutics (NRIX) stake by 4% in Q1 2026, buying an estimated $113K and bringing the position to 179,177 shares worth $2.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1366.

Manulife (Manufacturers Life Insurance) first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $3.28M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 179,177 shares of Nurix Therapeutics worth $2.78M as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) bought 6,813 Nurix Therapeutics shares in Q1 2026, an estimated $113K.
  • Nurix Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1366 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Nurix Therapeutics position peaked at $3.28M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.